Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Colorectal Neoplasms

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 294 articles:
HTML format



Single Articles


    July 2021
  1. WATTS K, Wills C, Madi A, Palles C, et al
    Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer.
    Int J Cancer. 2021 Jul 16. doi: 10.1002/ijc.33739.
    PubMed     Abstract available


  2. CHENG CY, Datzmann T, Hernandez D, Schmitt J, et al
    Do certified cancer centers provide more cost-effective care? A health economic analysis of colon cancer care in Germany using administrative data.
    Int J Cancer. 2021 Jul 2. doi: 10.1002/ijc.33728.
    PubMed     Abstract available


  3. PAPADIMITRIOU N, Gunter MJ, Murphy N, Gicquiau A, et al
    Circulating tryptophan metabolites and risk of colon cancer: results from case-control and prospective cohort studies.
    Int J Cancer. 2021 Jul 1. doi: 10.1002/ijc.33725.
    PubMed     Abstract available


    June 2021
  4. GULLICKSON C, Goodman M, Joko-Fru YW, Gnangnon FHR, et al
    Colorectal cancer survival in sub-Saharan Africa by age, stage at diagnosis, and Human Development Index: A population-based registry study.
    Int J Cancer. 2021 Jun 24. doi: 10.1002/ijc.33715.
    PubMed     Abstract available


  5. CHAUDHARY N, Choudhary BS, Shah SG, Khapare N, et al
    Lipocalin 2 expression promotes tumor progression and therapy resistance by inhibiting ferroptosis in colorectal cancer.
    Int J Cancer. 2021 Jun 19. doi: 10.1002/ijc.33711.
    PubMed     Abstract available



  6. Retraction: DCLK1 promotes epithelial-mesenchymal transition via the PI3K/Akt/NF-kB pathway in colorectal cancer. Weiying Liu, Shixing Wang, Qi Sun, Zhen Yang, Min Liu and Hua Tang. Int J Cancer. 2018 May 15;142(10):2068-2079.
    Int J Cancer. 2021 Jun 1. doi: 10.1002/ijc.33671.
    PubMed    


    May 2021
  7. ZORZI M, Battagello J, Fiore A, Memo L, et al
    Colorectal cancer incidence and mortality after negative fecal immunochemical tests by age 70: a prospective observational study.
    Int J Cancer. 2021 May 14. doi: 10.1002/ijc.33682.
    PubMed     Abstract available


  8. HAMFJORD J, Guren TK, Glimelius B, Sorbye H, et al
    Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS- or BRAF-mutated metastatic colorectal cancer.
    Int J Cancer. 2021 May 7. doi: 10.1002/ijc.33672.
    PubMed     Abstract available


  9. SHAH R, Chan KKW
    The Impact of Socioeconomic Status on Stage at Presentation, Receipt of Diagnostic Imaging, Receipt of Treatment, and Overall Survival in Colorectal Cancer Patients.
    Int J Cancer. 2021 May 5. doi: 10.1002/ijc.33622.
    PubMed     Abstract available


  10. FANG Z, Hang D, Wang K, Joshi A, et al
    Risk prediction models for colorectal cancer: evaluating the discrimination due to added biomarkers.
    Int J Cancer. 2021 May 5. doi: 10.1002/ijc.33621.
    PubMed     Abstract available


  11. VAUGHAN-SHAW PG, Timofeeva M, Ooi LY, Svinti V, et al
    Differential genetic influences over colorectal cancer risk and gene expression in large bowel mucosa.
    Int J Cancer. 2021 May 2. doi: 10.1002/ijc.33616.
    PubMed     Abstract available


    April 2021
  12. AGLAGO EK, Murphy N, Huybrechts I, Nicolas G, et al
    Dietary intake and plasma phospholipid concentrations of saturated, monounsaturated and trans fatty acids and colorectal cancer risk in the EPIC cohort.
    Int J Cancer. 2021 Apr 28. doi: 10.1002/ijc.33615.
    PubMed     Abstract available


  13. LEE SH, Song IH, Jang HJ
    Feasibility of deep learning-based fully automated classification of microsatellite instability in tissue slides of colorectal cancer.
    Int J Cancer. 2021 Apr 13. doi: 10.1002/ijc.33599.
    PubMed     Abstract available


  14. WANG Y, Zhang Y, Qian Y, Xie YH, et al
    Alterations in the Oral and Gut Microbiome of Colorectal Cancer Patients and Association with Host Clinical Factors.
    Int J Cancer. 2021 Apr 12. doi: 10.1002/ijc.33596.
    PubMed     Abstract available


  15. DORIA-ROSE VP, Lansdorp-Vogelaar I, McCarthy S, Puricelli-Perin DM, et al
    Measures of longitudinal adherence to fecal-based colorectal cancer screening: literature review and recommended approaches.
    Int J Cancer. 2021 Apr 3. doi: 10.1002/ijc.33589.
    PubMed     Abstract available


    March 2021
  16. ZHOU J, Ge X, Fan X, Wang J, et al
    Associations of vitamin D status with colorectal cancer risk and survival.
    Int J Cancer. 2021 Mar 30. doi: 10.1002/ijc.33580.
    PubMed     Abstract available


  17. INDUKURI R, Jafferali MH, Song D, Damdimopoulos A, et al
    Genome-Wide Estrogen Receptor beta Chromatin Binding in Human Colon Cancer Cells Reveals its Tumor Suppressor Activity.
    Int J Cancer. 2021 Mar 22. doi: 10.1002/ijc.33573.
    PubMed     Abstract available


  18. HELGADOTTIR HT, Thutkawkorapin J, Rohlin A, Nordling M, et al
    Identification of known and novel familial cancer genes in Swedish colorectal cancer families.
    Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33567.
    PubMed     Abstract available


  19. WEBSTER-CLARK M, Keil AP, Sanoff HK, Sturmer T, et al
    Introducing Longitudinal Cumulative Dose to Describe Chemotherapy Patterns Over Time: Case Study of a Colon Cancer Trial.
    Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33565.
    PubMed     Abstract available


  20. QU X, Zhao L, Wang M, Zhang R, et al
    Novel functional variants in the Notch pathway and survival of Chinese colorectal cancer.
    Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33561.
    PubMed     Abstract available


  21. VISCONTI P, Parodi F, Parodi B, Casarino L, et al
    Short tandem repeat profiling for the authentication of cancer stem-like cells.
    Int J Cancer. 2021;148:1489-1498.
    PubMed     Abstract available


  22. SHEN X, Shen X
    A potential role for aspirin in the prevention and treatment of cholangiocarcinoma.
    Int J Cancer. 2021;148:1323-1330.
    PubMed     Abstract available


    February 2021
  23. KIM H, Wang K, Song M, Giovannucci EL, et al
    A comparison of methods in estimating population attributable risk for colorectal cancer in the United States.
    Int J Cancer. 2021 Feb 2. doi: 10.1002/ijc.33489.
    PubMed     Abstract available


  24. HEIDRICH I, Ackar L, Mossahebi Mohammadi P, Pantel K, et al
    Liquid biopsies: Potential and challenges.
    Int J Cancer. 2021;148:528-545.
    PubMed     Abstract available


    January 2021
  25. MAKI-NEVALA S, Ukwattage S, Olkinuora A, Almusa H, et al
    Somatic mutation profiles as molecular classifiers of ulcerative colitis-associated colorectal cancer.
    Int J Cancer. 2021 Jan 31. doi: 10.1002/ijc.33492.
    PubMed     Abstract available


  26. JONGENEEL G, Greuter MJ, van Erning FN, Twisk JW, et al
    Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients: a prospective cohort study.
    Int J Cancer. 2021 Jan 18. doi: 10.1002/ijc.33472.
    PubMed     Abstract available


  27. DOMINGUEZ-VALENTIN M, Sampson JR, Moller P, Seppala TT, et al
    Analysis in the Prospective Lynch Syndrome Database identifies sarcoma as part of the Lynch syndrome tumor spectrum.
    Int J Cancer. 2021;148:512-513.
    PubMed    


  28. HE Y, Timofeeva M, Zhang X, Xu W, et al
    Colorectal cancer risk variants rs10161980 and rs7495132 are associated with cancer survival outcome by a recessive mode of inheritance.
    Int J Cancer. 2021 Jan 7. doi: 10.1002/ijc.33465.
    PubMed     Abstract available


  29. WANG L, Hang D, He X, Lo CH, et al
    A prospective study of erythrocyte polyunsaturated fatty acids and risk of colorectal serrated polyps and conventional adenomas.
    Int J Cancer. 2021;148:57-66.
    PubMed     Abstract available


    December 2020
  30. LONG L, Yang W, Liu L, Tobias DK, et al
    Dietary intake of branched-chain amino acids and survival after colorectal cancer diagnosis.
    Int J Cancer. 2020 Dec 19. doi: 10.1002/ijc.33449.
    PubMed     Abstract available


  31. JENSEN BV, Schou JV, Yilmaz M, Johannesen HH, et al
    Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status.
    Int J Cancer. 2020 Dec 17. doi: 10.1002/ijc.33448.
    PubMed     Abstract available


  32. HEISSER T, Hoffmeister M, Brenner H
    Effects of Screening for Colorectal Cancer: Development, Documentation and Validation of a Multistate Markov Model.
    Int J Cancer. 2020 Dec 15. doi: 10.1002/ijc.33437.
    PubMed     Abstract available


  33. ORNTOFT MW, Jensen SO, Ogaard N, Henriksen TV, et al
    Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer.
    Int J Cancer. 2020 Dec 15. doi: 10.1002/ijc.33434.
    PubMed     Abstract available


  34. INNOMINATO PF, Karaboue A, Focan C, Chollet P, et al
    Efficacy and safety of chronomodulated Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: results from the international EORTC 05011 trial.
    Int J Cancer. 2020 Dec 3. doi: 10.1002/ijc.33422.
    PubMed     Abstract available


    November 2020
  35. BLAKER H, Haupt S, Morak M, Holinski-Feder E, et al
    Age-dependent performance of BRAF mutation testing in Lynch syndrome diagnostics.
    Int J Cancer. 2020;147:2801-2810.
    PubMed     Abstract available


  36. ZHAN T, Faehling V, Rauscher B, Betge J, et al
    Multi-omics integration identifies a selective vulnerability of colorectal cancer subtypes to YM155.
    Int J Cancer. 2020 Nov 13. doi: 10.1002/ijc.33393.
    PubMed    


    October 2020
  37. THURMAIER J, Heinemann V, Engel J, Schubert-Fritschle G, et al
    Patients with colorectal cancer and brain metastasis: The relevance of extracranial metastatic patterns predicting time intervals to first occurrence of intracranial metastasis and survival.
    Int J Cancer. 2020 Oct 28. doi: 10.1002/ijc.33364.
    PubMed     Abstract available


  38. HE MM, Fang Z, Hang D, Wang F, et al
    Circulating Liver Function Markers and Colorectal Cancer Risk: A Prospective Cohort Study in the UK Biobank.
    Int J Cancer. 2020 Oct 22. doi: 10.1002/ijc.33351.
    PubMed     Abstract available


  39. LI L, Duan Q, Zeng Z, Zhao J, et al
    UHRF2 promotes intestinal tumorigenesis through stabilization of TCF4 mediated Wnt/beta-catenin signaling.
    Int J Cancer. 2020;147:2239-2252.
    PubMed     Abstract available


  40. LANG M, Baumgartner M, Rozalska A, Frick A, et al
    Crypt residing bacteria and proximal colonic carcinogenesis in a mouse model of Lynch syndrome.
    Int J Cancer. 2020;147:2316-2326.
    PubMed     Abstract available


  41. SCHLICKER A, Ellappalayam A, Beumer IJ, Snel MHJ, et al
    Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis.
    Int J Cancer. 2020;147:2303-2315.
    PubMed     Abstract available


  42. PILLERON S, Charvat H, Araghi M, Arnold M, et al
    Age disparities in stage-specific colon cancer survival across seven countries: an ICBP SURVMARK-2 population-based study.
    Int J Cancer. 2020 Oct 2. doi: 10.1002/ijc.33326.
    PubMed     Abstract available


  43. JARY M, Hasanova R, Vienot A, Asgarov K, et al
    Molecular description of ANGPT2 associated colorectal carcinoma.
    Int J Cancer. 2020;147:2007-2018.
    PubMed     Abstract available


    September 2020
  44. TIE J, Cohen JD, Lo SN, Wang Y, et al
    Prognostic Significance of Post-Surgery Circulating Tumor DNA in Non-Metastatic Colorectal Cancer: Individual Patient Pooled Analysis of Three Cohort Studies.
    Int J Cancer. 2020 Sep 27. doi: 10.1002/ijc.33312.
    PubMed     Abstract available


  45. UNSELD M, Belic J, Pierer K, Zhou Q, et al
    A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy (RELAIS) translational biomarker phase II pilot study.
    Int J Cancer. 2020 Sep 19. doi: 10.1002/ijc.33303.
    PubMed     Abstract available


  46. ETTRICH TJ, Perkhofer L, Decker T, Hofheinz RD, et al
    Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: the randomized, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111).
    Int J Cancer. 2020 Sep 15. doi: 10.1002/ijc.33296.
    PubMed     Abstract available


  47. LADIGAN-BADURA S, Vangala DB, Engel C, Bucksch K, et al
    Value of upper GI endoscopy for gastric cancer surveillance in patients with Lynch syndrome.
    Int J Cancer. 2020 Sep 15. doi: 10.1002/ijc.33294.
    PubMed     Abstract available


  48. GIANNINI V, Rosati S, Defeudis A, Balestra G, et al
    Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy.
    Int J Cancer. 2020 Sep 1. doi: 10.1002/ijc.33271.
    PubMed     Abstract available


  49. JANAKIRAMAN H, Zhu Y, Becker SA, Wang C, et al
    Modeling rectal cancer to advance neoadjuvant precision therapy.
    Int J Cancer. 2020;147:1405-1418.
    PubMed     Abstract available


    August 2020
  50. TAYLOR JC, Swinson D, Seligmann JF, Birch RJ, et al
    Addressing the variation in adjuvant chemotherapy treatment for colorectal cancer: can a regional intervention promote national change?
    Int J Cancer. 2020 Aug 20. doi: 10.1002/ijc.33261.
    PubMed     Abstract available


  51. ACHILLI P, Crippa J, Grass F, Larson DW, et al
    Reply to: Comments on "Survival impact of adjuvant chemotherapy in patients with stage IIA colon cancer: Analysis of the National Cancer Database".
    Int J Cancer. 2020 Aug 15. doi: 10.1002/ijc.33256.
    PubMed    


  52. DIZDAR O
    Comments on "Survival impact of adjuvant chemotherapy in patients with stage IIA colon cancer: Analysis of the National Cancer Database".
    Int J Cancer. 2020 Aug 15. doi: 10.1002/ijc.33258.
    PubMed    


  53. AKTER S, Islam Z, Mizoue T, Sawada N, et al
    Smoking and colorectal cancer: a pooled analysis of ten population-based cohort studies in Japan.
    Int J Cancer. 2020 Aug 5. doi: 10.1002/ijc.33248.
    PubMed     Abstract available


  54. LOOPIK DL, Ebisch RM, IntHout J, Melchers WJ, et al
    The relative risk of noncervical high-risk human papillomavirus-related (pre)malignancies after recurrent cervical intraepithelial neoplasia grade 3: A population-based study.
    Int J Cancer. 2020;147:897-900.
    PubMed     Abstract available


  55. WALPOLE E, Dunn N, Youl P, Harden H, et al
    Nonbreast cancer incidence, treatment received and outcomes: Are there differences in breast screening attendees versus nonattendees?
    Int J Cancer. 2020;147:856-865.
    PubMed     Abstract available


  56. TAO W, Artama M, von Euler-Chelpin M, Hull M, et al
    Colon and rectal cancer risk after bariatric surgery in a multicountry Nordic cohort study.
    Int J Cancer. 2020;147:728-735.
    PubMed     Abstract available


  57. CARIOLI G, Bertuccio P, Malvezzi M, Rodriguez T, et al
    Cancer mortality predictions for 2019 in Latin America.
    Int J Cancer. 2020;147:619-632.
    PubMed     Abstract available


    July 2020
  58. LINDNER AU, Carberry S, Monsefi N, Barat A, et al
    Systems analysis of protein signatures predicting Cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenografts models of metastatic colorectal cancer.
    Int J Cancer. 2020 Jul 23. doi: 10.1002/ijc.33226.
    PubMed     Abstract available


  59. AHADOVA A, Seppala TT, Engel C, Gallon R, et al
    The "unnatural" history of colorectal cancer in Lynch syndrome: lessons from colonoscopy surveillance.
    Int J Cancer. 2020 Jul 19. doi: 10.1002/ijc.33224.
    PubMed     Abstract available


  60. FELGNER S, Sporing I, Pawar V, Kocijancic D, et al
    The immunogenic potential of bacterial flagella for Salmonella-mediated tumor therapy.
    Int J Cancer. 2020;147:448-460.
    PubMed     Abstract available


  61. AKCAY IM, Celik E, Agaoglu NB, Alkurt G, et al
    Germline pathogenic variant spectrum in 25 cancer susceptibility genes in Turkish breast and colorectal cancer patients and elderly controls.
    Int J Cancer. 2020 Jul 13. doi: 10.1002/ijc.33199.
    PubMed     Abstract available


  62. MATSUYAMA T, Kandimalla R, Ishikawa T, Takahashi N, et al
    A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer.
    Int J Cancer. 2020 Jul 13. doi: 10.1002/ijc.33129.
    PubMed     Abstract available


  63. HAMERS PAH, Elferink MAG, Stellato RK, Punt CJA, et al
    Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real-life data.
    Int J Cancer. 2020 Jul 7. doi: 10.1002/ijc.33200.
    PubMed     Abstract available


  64. NGUYEN S, Li H, Yu D, Cai H, et al
    Dietary Fatty Acids and Colorectal Cancer Risk in Men: A Report from the Shanghai Men's Health Study and a Meta-Analysis.
    Int J Cancer. 2020 Jul 7. doi: 10.1002/ijc.33196.
    PubMed     Abstract available


  65. ACHILLI P, Crippa J, Grass F, Mathis KL, et al
    Survival impact of adjuvant chemotherapy in patients with Stage IIA colon cancer: analysis of the National Cancer Database.
    Int J Cancer. 2020 Jul 7. doi: 10.1002/ijc.33203.
    PubMed     Abstract available


  66. LI X, Timofeeva M, Spiliopoulou A, McKeigue P, et al
    Prediction of Colorectal Cancer Risk Based on Profiling with Common Genetic Variants.
    Int J Cancer. 2020 Jul 7. doi: 10.1002/ijc.33191.
    PubMed     Abstract available


  67. CLIFFORD GM, Georges D, Shiels MS, Engels EA, et al
    A meta-analysis of anal cancer incidence by risk group: towards a unified anal cancer risk scale.
    Int J Cancer. 2020 Jul 4. doi: 10.1002/ijc.33185.
    PubMed     Abstract available


  68. PONTI A, Basu P, Ritchie D, Anttila A, et al
    Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening.
    Int J Cancer. 2020;147:9-13.
    PubMed     Abstract available


    June 2020
  69. LEE HS, Lee S, Cho KH
    Cotargeting BET proteins overcomes resistance arising from PI3K/mTOR blockade-induced protumorigenic senescence in colorectal cancer.
    Int J Cancer. 2020 Jun 29. doi: 10.1002/ijc.33047.
    PubMed     Abstract available


  70. VOS JR, Fakkert IE, Spruijt L, Willems RW, et al
    Evaluation of yield and experiences of age-related molecular investigation for heritable and nonheritable causes of mismatch repair deficient colorectal cancer to identify Lynch syndrome.
    Int J Cancer. 2020 Jun 8. doi: 10.1002/ijc.33117.
    PubMed     Abstract available


    May 2020
  71. TOLBA MF
    Revolutionizing the Landscape of Colorectal Cancer Treatment: The Potential Role of Immune Checkpoint Inhibitors.
    Int J Cancer. 2020 May 16. doi: 10.1002/ijc.33056.
    PubMed     Abstract available


  72. HWANG JH, Yoon J, Cho YH, Cha PH, et al
    A mutant KRAS-induced factor REG4 promotes cancer stem cell properties via Wnt/beta-catenin signaling.
    Int J Cancer. 2020;146:2877-2890.
    PubMed     Abstract available


  73. GIBBS DC, Bostick RM, McCullough M, Um C, et al
    Association of pre-diagnostic vitamin D status with mortality among colorectal cancer patients differs by common, inherited vitamin D-binding protein isoforms.
    Int J Cancer. 2020 May 11. doi: 10.1002/ijc.33043.
    PubMed     Abstract available


  74. NISHINO J, Watanabe S, Miya F, Kamatani T, et al
    Quantification of multicellular colonization in tumor metastasis using exome-sequencing data.
    Int J Cancer. 2020;146:2488-2497.
    PubMed     Abstract available


  75. ARRIGA R, Caratelli S, Lanzilli G, Ottaviani A, et al
    CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab.
    Int J Cancer. 2020;146:2531-2538.
    PubMed     Abstract available


  76. PUCA E, Probst P, Stringhini M, Murer P, et al
    The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8(+) T cell activity and synergizes with immune checkpoint inhibitors.
    Int J Cancer. 2020;146:2518-2530.
    PubMed     Abstract available


  77. KOBA R, Fujita H, Nishibori M, Saeki K, et al
    Quantitative evaluation of the intratumoral distribution of platinum in oxaliplatin-treated rectal cancer: In situ visualization of platinum via synchrotron radiation X-ray fluorescence spectrometry.
    Int J Cancer. 2020;146:2498-2509.
    PubMed     Abstract available


  78. HANYUDA A, Lee DH, Ogino S, Wu K, et al
    Long-term status of predicted body fat percentage, body mass index and other anthropometric factors with risk of colorectal carcinoma: Two large prospective cohort studies in the US.
    Int J Cancer. 2020;146:2383-2393.
    PubMed     Abstract available


    April 2020
  79. BOAKYE D, Jansen L, Schottker B, Jansen EHJM, et al
    Blood markers of oxidative stress are strongly associated with poorer prognosis in colorectal cancer patients.
    Int J Cancer. 2020 Apr 22. doi: 10.1002/ijc.33018.
    PubMed     Abstract available


  80. KIM N, Cho D, Kim H, Kim S, et al
    Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab.
    Int J Cancer. 2020;146:2194-2200.
    PubMed     Abstract available


  81. KOMOR MA, de Wit M, van den Berg J, Martens de Kemp SR, et al
    Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression.
    Int J Cancer. 2020;146:1979-1992.
    PubMed     Abstract available


  82. LIU T, Song X, Khan S, Li Y, et al
    The gut microbiota at the intersection of bile acids and intestinal carcinogenesis: An old story, yet mesmerizing.
    Int J Cancer. 2020;146:1780-1790.
    PubMed     Abstract available


    March 2020
  83. HUANG WK, Chang SH, Hsu HC, Chou WC, et al
    Postdiagnostic Metformin Use and Survival of Patients With Colorectal Cancer: A Nationwide Cohort study.
    Int J Cancer. 2020 Mar 20. doi: 10.1002/ijc.32989.
    PubMed     Abstract available


  84. TOKUNAGA R, Nakagawa S, Sakamoto Y, Nakamura K, et al
    12-chemokine signature, a predictor of tumor recurrence in colorectal cancer.
    Int J Cancer. 2020 Mar 19. doi: 10.1002/ijc.32982.
    PubMed     Abstract available


  85. DASHTI SG, Viallon V, Simpson JA, Karahalios A, et al
    Explaining the link between adiposity and colorectal cancer risk in men and postmenopausal women in the UK Biobank: a sequential causal mediation analysis.
    Int J Cancer. 2020 Mar 17. doi: 10.1002/ijc.32980.
    PubMed     Abstract available


  86. FRANKE FC, Slusarenko BO, Engleitner T, Johannes W, et al
    Novel role for CRK adaptor proteins as essential components of SRC/FAK signaling for epithelial-mesenchymal transition and colorectal cancer aggressiveness.
    Int J Cancer. 2020 Mar 9. doi: 10.1002/ijc.32955.
    PubMed     Abstract available



  87. Inhibition of SLC1A5 sensitizes colorectal cancer to cetuximab.
    Int J Cancer. 2020;146:E26.
    PubMed    


    February 2020
  88. MOHRMANN L, Zowada MK, Strakerjahn H, Siegl C, et al
    A Perivascular Niche in the Bone Marrow Hosts Quiescent and Proliferating Tumorigenic Colorectal Cancer Cells.
    Int J Cancer. 2020 Feb 19. doi: 10.1002/ijc.32933.
    PubMed     Abstract available


  89. ZANUTTO S, Ciniselli CM, Belfiore A, Lecchi M, et al
    Plasma miRNA-based signatures in CRC screening programs.
    Int J Cancer. 2020;146:1164-1173.
    PubMed     Abstract available


  90. LOPES A, Billard E, Casse AH, Villeger R, et al
    Colibactin-positive E. coli induce a pro-carcinogenic immune environment leading to immunotherapy resistance in colorectal cancer.
    Int J Cancer. 2020 Feb 9. doi: 10.1002/ijc.32920.
    PubMed     Abstract available


  91. DONG L, Jin X, Wang W, Ye Q, et al
    Distinct clinical phenotype and genetic testing strategy for Lynch syndrome in China based on a large colorectal cancer cohort.
    Int J Cancer. 2020 Feb 6. doi: 10.1002/ijc.32914.
    PubMed     Abstract available


    January 2020
  92. MORETTO R, Falcone A, Cremolini C
    Duration of oxaliplatin-based adjuvant chemotherapy in patients with stage III or high-risk stage II resected colon cancer.
    Int J Cancer. 2020 Jan 22. doi: 10.1002/ijc.32884.
    PubMed    


  93. TOUGERON D, Sueur B, Zaanan A, De La Fouchardiere C, et al
    Prognosis and Chemosensitivity of Deficient MMR Phenotype in Patients with Metastatic Colorectal Cancer: an AGEO Retrospective Multicenter Study.
    Int J Cancer. 2020 Jan 22. doi: 10.1002/ijc.32879.
    PubMed     Abstract available


  94. JAKSZYN P, Cayssials V, Buckland G, Perez-Cornago A, et al
    Inflammatory potential of the diet and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) study.
    Int J Cancer. 2020 Jan 16. doi: 10.1002/ijc.32870.
    PubMed     Abstract available


  95. PARDINI B, Corrado A, Paolicchi E, Cugliari G, et al
    DNA repair and cancer in colon and rectum: Novel players in genetic susceptibility.
    Int J Cancer. 2020;146:363-372.
    PubMed     Abstract available


  96. AMITAY EL, Carr PR, Jansen L, Alwers E, et al
    Postmenopausal hormone replacement therapy and colorectal cancer risk by molecular subtypes and pathways.
    Int J Cancer. 2020 Jan 14. doi: 10.1002/ijc.32868.
    PubMed     Abstract available


  97. DI J, Liu M, Fan Y, Gao P, et al
    Phenotype Molding of T Cells in Colorectal Cancer by Single-cell Analysis.
    Int J Cancer. 2020 Jan 4. doi: 10.1002/ijc.32856.
    PubMed     Abstract available


  98. BJERRUM A, Lindebjerg J, Andersen O, Fischer A, et al
    Long term risk of colorectal cancer after screen detected adenoma: Experiences from a Danish gFOBT positive screening cohort.
    Int J Cancer. 2020 Jan 2. doi: 10.1002/ijc.32850.
    PubMed     Abstract available


  99. SCLAFANI F, Wilson SH, Cunningham D, Gonzalez De Castro D, et al
    Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
    Int J Cancer. 2020;146:94-102.
    PubMed     Abstract available


    December 2019
  100. ABRAHAMSSON H, Jensen BV, Berven LL, Nielsen DL, et al
    Antitumour immunity invoked by hepatic arterial infusion of first-line oxaliplatin predicts durable colorectal cancer control after liver metastasis ablation; 8-12 years of follow-up.
    Int J Cancer. 2019 Dec 24. doi: 10.1002/ijc.32847.
    PubMed     Abstract available


  101. YANG W, Giovannucci EL, Hankinson SE, Chan AT, et al
    Endogenous sex hormones and colorectal cancer survival among men and women.
    Int J Cancer. 2019 Dec 21. doi: 10.1002/ijc.32844.
    PubMed     Abstract available


  102. KOOYKER AI, Toes-Zoutendijk E, Opstal-van Winden AWJ, Spaander MCW, et al
    The Second Round of The Dutch Colorectal Cancer Screening Program: Impact of An Increased Fit Cut-Off Level on Yield of Screening.
    Int J Cancer. 2019 Dec 19. doi: 10.1002/ijc.32839.
    PubMed     Abstract available


  103. WOLSTENHOLME J, Fusco F, Gray AM, Moschandreas J, et al
    Quality of life in the FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised trials of selective internal radiotherapy for metastatic colorectal cancer.
    Int J Cancer. 2019 Dec 16. doi: 10.1002/ijc.32828.
    PubMed     Abstract available


  104. TAKEGAWA N, Tsurutani J, Kawakami H, Yonesaka K, et al
    [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.
    Int J Cancer. 2019;145:3414-3424.
    PubMed     Abstract available


  105. BOIGE V, Mollevi C, Gourgou S, Azria D, et al
    Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial.
    Int J Cancer. 2019;145:3163-3172.
    PubMed     Abstract available


    November 2019
  106. NOH H, Charvat H, Freisling H, Olafsdottir GH, et al
    Cumulative exposure to premenopausal obesity and risk of postmenopausal cancer: A population-based study in Icelandic women.
    Int J Cancer. 2019 Nov 21. doi: 10.1002/ijc.32805.
    PubMed     Abstract available


  107. IIOKA H, Saito K, Sakaguchi M, Tachibana T, et al
    Crumbs3 is a critical factor that regulates invasion and metastasis of colon adenocarcinoma via the specific interaction with FGFR1.
    Int J Cancer. 2019;145:2740-2753.
    PubMed     Abstract available


  108. WANG Q, Wang Y, Liu Y, Zhang C, et al
    U2-related proteins CHERP and SR140 contribute to colorectal tumorigenesis via alternative splicing regulation.
    Int J Cancer. 2019;145:2728-2739.
    PubMed     Abstract available


  109. COMBES JD, Clifford GM, Gunthard HF, Hauser C, et al
    Antibodies against HPV16E6 oncoprotein in the Swiss HIV Cohort Study: kinetics and anal cancer risk prediction.
    Int J Cancer. 2019 Nov 12. doi: 10.1002/ijc.32784.
    PubMed     Abstract available


  110. GE W, Hu H, Cai W, Xu J, et al
    High-risk stage III colon cancer patients identified by a novel 5-gene mutational signature are characterized by up-regulation of IL-23A and gut bacterial translocation of the tumor microenvironment.
    Int J Cancer. 2019 Nov 6. doi: 10.1002/ijc.32775.
    PubMed     Abstract available


    October 2019
  111. XU W, Zhou G, Wang H, Liu Y, et al
    Circulating lncRNA SNHG11 as a novel biomarker for early diagnosis and prognosis of colorectal cancer.
    Int J Cancer. 2019 Oct 21. doi: 10.1002/ijc.32747.
    PubMed     Abstract available


  112. KYUNO D, Zhao K, Schnolzer M, Provaznik J, et al
    Claudin7-dependent exosome-promoted reprogramming of nonmetastasizing tumor cells.
    Int J Cancer. 2019;145:2182-2200.
    PubMed     Abstract available


  113. DIEFENHARDT M, Hofheinz RD, Martin D, Beissbarth T, et al
    Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial.
    Int J Cancer. 2019;145:2282-2291.
    PubMed     Abstract available


  114. LI Z, Zhou J, Zhang J, Li S, et al
    Cancer-associated fibroblasts promote PD-L1 expression in mice cancer cells via secreting CXCL5.
    Int J Cancer. 2019;145:1946-1957.
    PubMed     Abstract available


  115. CACHEUX W, Lievre A, Richon S, Vacher S, et al
    Interaction between IGF2-PI3K axis and cancer-associated-fibroblasts promotes anal squamous carcinogenesis.
    Int J Cancer. 2019;145:1852-1859.
    PubMed     Abstract available


    September 2019
  116. DEOULA MS, El Kinany K, Huybrechts I, Gunter MJ, et al
    Consumption of meat, traditional and modern processed meat and colorectal cancer risk among the Moroccan population: A large-scale case-control study.
    Int J Cancer. 2019 Sep 16. doi: 10.1002/ijc.32689.
    PubMed     Abstract available


  117. TOMA C, Diaz-Gay M, Franch-Exposito S, Arnau-Collell C, et al
    Using linkage studies combined with whole-exome sequencing to identify novel candidate genes for familial colorectal cancer.
    Int J Cancer. 2019 Sep 16. doi: 10.1002/ijc.32683.
    PubMed     Abstract available


  118. LIN Y, Ma C, Bezabeh T, Wang Z, et al
    (1) H NMR-based metabolomics reveal overlapping discriminatory metabolites and metabolic pathway disturbances between colorectal tumor tissues and fecal samples.
    Int J Cancer. 2019;145:1679-1689.
    PubMed     Abstract available


  119. TIAN J, Ying P, Ke J, Zhu Y, et al
    ANKLE1 N(6) -Methyladenosine-related variant is associated with colorectal cancer risk by maintaining the genomic stability.
    Int J Cancer. 2019 Sep 11. doi: 10.1002/ijc.32677.
    PubMed     Abstract available


  120. MIZUKOSHI K, Okazawa Y, Haeno H, Koyama Y, et al
    Metastatic seeding of human colon cancer cell clusters expressing the hybrid epithelial/mesenchymal state.
    Int J Cancer. 2019 Sep 10. doi: 10.1002/ijc.32672.
    PubMed     Abstract available


  121. GEIJSEN AJMR, van Roekel EH, van Duijnhoven FJB, Achaintre D, et al
    Plasma metabolites associated with colorectal cancer stage: findings from an international consortium.
    Int J Cancer. 2019 Sep 8. doi: 10.1002/ijc.32666.
    PubMed     Abstract available


  122. GRUNEWALD S, Politz O, Bender S, Heroult M, et al
    Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.
    Int J Cancer. 2019;145:1346-1357.
    PubMed     Abstract available


    August 2019
  123. MOATI E, Blons H, Taly V, Garlan F, et al
    Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer.
    Int J Cancer. 2019 Aug 31. doi: 10.1002/ijc.32657.
    PubMed     Abstract available


  124. FREIHEN V, Ronsch K, Mastroianni J, Frey P, et al
    SNAIL1 employs beta-Catenin-LEF1 complexes to control colorectal cancer cell invasion and proliferation.
    Int J Cancer. 2019 Aug 28. doi: 10.1002/ijc.32644.
    PubMed     Abstract available


  125. JONGENEEL G, Klausch T, van Erning FN, Vink GR, et al
    Estimating adjuvant treatment effects in stage II colon cancer: comparing the synthesis of randomized clinical trial data to real world data.
    Int J Cancer. 2019 Aug 19. doi: 10.1002/ijc.32629.
    PubMed     Abstract available


  126. CALLEJAS BE, Mendoza-Rodriguez MG, Villamar-Cruz O, Reyes-Martinez S, et al
    Helminth-derived molecules inhibit colitis-associated colon cancer development through NF-kB and STAT3 regulation.
    Int J Cancer. 2019 Aug 13. doi: 10.1002/ijc.32626.
    PubMed     Abstract available


  127. GALAINE J, Turco C, Vauchy C, Royer B, et al
    CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin.
    Int J Cancer. 2019 Aug 9. doi: 10.1002/ijc.32620.
    PubMed     Abstract available


  128. DENG X, Ruan H, Zhang X, Xu X, et al
    Long non-coding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells.
    Int J Cancer. 2019 Aug 5. doi: 10.1002/ijc.32608.
    PubMed     Abstract available


  129. WEI F, Su Y, Yao X, Cui X, et al
    Sex differences in the incidence and clearance of anal human papillomavirus infection among heterosexual men and women in Liuzhou, China: An observational cohort study.
    Int J Cancer. 2019;145:807-816.
    PubMed     Abstract available


  130. BLANKS R, Buron Pust A, Alison R, He E, et al
    Screen-detected and interval colorectal cancers in England: Associations with lifestyle and other factors in women in a large UK prospective cohort.
    Int J Cancer. 2019;145:728-734.
    PubMed     Abstract available


  131. BENGS S, Becker E, Busenhart P, Spalinger MR, et al
    beta6 -integrin serves as a novel serum tumor marker for colorectal carcinoma.
    Int J Cancer. 2019;145:678-685.
    PubMed     Abstract available


    July 2019
  132. DEMONTOUX L, Derangere V, Pilot T, Thinselin C, et al
    Hypotonic stress enhances colon cancer cell death induced by platinum derivatives and immunologically improves anti-tumor efficacy of intraperitoneal chemotherapy.
    Int J Cancer. 2019 Jul 25. doi: 10.1002/ijc.32590.
    PubMed     Abstract available


  133. GUO F, Chen C, Schottker B, Holleczek B, et al
    Changes in colorectal cancer screening use after introduction of alternative screening offer in Germany: Prospective cohort study.
    Int J Cancer. 2019 Jul 10. doi: 10.1002/ijc.32566.
    PubMed     Abstract available


  134. REINHOLDT K, Thomsen LT, Dehlendorff C, Larsen HK, et al
    Human papillomavirus (HPV)-related anogenital premalignancies and cancer in renal transplant recipients: a Danish nationwide, registry-based cohort study.
    Int J Cancer. 2019 Jul 10. doi: 10.1002/ijc.32565.
    PubMed     Abstract available


  135. KARIV R, Caspi M, Fliss-Isakov N, Shorer Y, et al
    Resorting the function of the colorectal cancer (CRC) gate keeper adenomatous Polyposis Coli (APC).
    Int J Cancer. 2019 Jul 8. doi: 10.1002/ijc.32557.
    PubMed     Abstract available


  136. HE Y, Theodoratou E, Li X, Din FV, et al
    Effects of common genetic variants associated with colorectal cancer risk on survival outcomes after diagnosis: a large population-based cohort study.
    Int J Cancer. 2019 Jul 4. doi: 10.1002/ijc.32550.
    PubMed     Abstract available


  137. MATTIOLI AV, Farinetti A, Gelmini R
    The beneficial effect of Mediterranean diet on colorectal cancer.
    Int J Cancer. 2019;145:306.
    PubMed    


  138. PORKKA N, Lahtinen L, Ahtiainen M, Bohm JP, et al
    Epidemiological, clinical and molecular characterization of Lynch-like syndrome: A population-based study.
    Int J Cancer. 2019;145:87-98.
    PubMed     Abstract available


  139. AI L, Ren Y, Li Y, Chen H, et al
    Synbindin deficiency inhibits colon carcinogenesis by attenuating Wnt cascade and balancing gut microbiome.
    Int J Cancer. 2019;145:206-220.
    PubMed     Abstract available


    June 2019

  140. Erratum: Association between metformin use after surgery for colorectal cancer and oncological outcomes: A nationwide register-based study.
    Int J Cancer. 2019;144:E9-E11.
    PubMed    


  141. BESHARA A, Ahoroni M, Comanester D, Vilkin A, et al
    Association Between Time to Colonoscopy After a Positive Guaiac Fecal Test Result and Risk of Colorectal Cancer and Advanced Stage Disease at Diagnosis.
    Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32497.
    PubMed     Abstract available


  142. MPUNGA T, Umulisa MC, Tenet V, Rugwizangoga B, et al
    Human papillomavirus genotypes in cervical and other HPV-related anogenital cancer in Rwanda, according to HIV status.
    Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32491.
    PubMed     Abstract available


  143. GUO TA, Wu YC, Tan C, Jin YT, et al
    Clinicopathologic features and prognostic value of KRAS, NRAS, and BRAF mutations and DNA mismatch repair status: a single-center retrospective study of 1834 Chinese patients with stage I-IV colorectal cancer.
    Int J Cancer. 2019 Jun 4. doi: 10.1002/ijc.32489.
    PubMed     Abstract available


    May 2019
  144. MORI N, Sawada N, Iwasaki M, Yamaji T, et al
    Circulating sex hormone levels and colorectal cancer risk in Japanese postmenopausal women: The JPHC nested case-control study.
    Int J Cancer. 2019 May 27. doi: 10.1002/ijc.32431.
    PubMed     Abstract available


  145. CHEN Y, Liu Z, Wang H, Tang Z, et al
    VPS33B negatively modulated by nicotine functions as a tumor suppressor in colorectal cancer.
    Int J Cancer. 2019 May 24. doi: 10.1002/ijc.32429.
    PubMed     Abstract available


  146. GAO X, Wilsgaard T, Jansen EH, Xuan Y, et al
    Serum total thiol levels and the risk of lung, colorectal, breast and prostate cancer: A prospective case-cohort study.
    Int J Cancer. 2019 May 24. doi: 10.1002/ijc.32428.
    PubMed     Abstract available


  147. HE X, Wu K, Zhang X, Nishihara R, et al
    Dietary intake of fiber, whole grains and risk of colorectal cancer: an updated analysis according to food sources, tumor location and molecular subtypes in two large US cohorts.
    Int J Cancer. 2019 May 1. doi: 10.1002/ijc.32382.
    PubMed     Abstract available


  148. CORNELISSEN LAM, Blanas A, van der Horst JC, Kruijssen L, et al
    Disruption of sialic acid metabolism drives tumor growth by augmenting CD8(+) T cell apoptosis.
    Int J Cancer. 2019;144:2290-2302.
    PubMed     Abstract available


  149. BAO C, Yang R, Pedersen NL, Xu W, et al
    Overweight in midlife and risk of cancer in late life: A nationwide Swedish twin study.
    Int J Cancer. 2019;144:2128-2134.
    PubMed     Abstract available


  150. ERBEN V, Carr PR, Holleczek B, Stegmaier C, et al
    Strong associations of a healthy lifestyle with all stages of colorectal carcinogenesis: Results from a large cohort of participants of screening colonoscopy.
    Int J Cancer. 2019;144:2135-2143.
    PubMed     Abstract available


  151. ENDRIS V, Buchhalter I, Allgauer M, Rempel E, et al
    Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.
    Int J Cancer. 2019;144:2303-2312.
    PubMed     Abstract available


  152. ZHANG K, Dai H, Liang W, Zhang L, et al
    Fermented dairy foods intake and risk of cancer.
    Int J Cancer. 2019;144:2099-2108.
    PubMed     Abstract available


    April 2019
  153. MCNABB S, Harrison TA, Albanes D, Berndt SI, et al
    Meta-analysis of 16 studies of the association of alcohol with colorectal cancer.
    Int J Cancer. 2019 Apr 29. doi: 10.1002/ijc.32377.
    PubMed     Abstract available


  154. KHAN N, Jajeh F, Eberhardt EL, Miller DD, et al
    Fisetin and 5-Fluorouracil: Effective Combination for PIK3CA-Mutant Colorectal Cancer.
    Int J Cancer. 2019 Apr 24. doi: 10.1002/ijc.32367.
    PubMed     Abstract available


  155. DE KORT S, Simons CCJM, van den Brandt PA, Janssen-Heijnen MLG, et al
    Diabetes mellitus, genetic variants in the insulin-like growth factor pathway and colorectal cancer risk.
    Int J Cancer. 2019 Apr 24. doi: 10.1002/ijc.32365.
    PubMed     Abstract available


  156. CHERNYAVSKIY P, Kennerley VM, Jemal A, Little MP, et al
    Heterogeneity of colon and rectum cancer incidence across 612 SEER counties, 2000-2014.
    Int J Cancer. 2019;144:1786-1795.
    PubMed     Abstract available


  157. CHENG WC, Liao TT, Lin CC, Yuan LE, et al
    RAB27B-activated secretion of stem-like tumor exosomes delivers the biomarker microRNA-146a-5p, which promotes tumorigenesis and associates with an immunosuppressive tumor microenvironment in colorectal cancer.
    Int J Cancer. 2019 Apr 13. doi: 10.1002/ijc.32338.
    PubMed     Abstract available


  158. MINI E, Lapucci A, Perrone G, D'Aurizio R, et al
    RNA sequencing reveals PNN and KCNQ1OT1as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy.
    Int J Cancer. 2019 Apr 11. doi: 10.1002/ijc.32326.
    PubMed     Abstract available


  159. OSUMI H, Shinozaki E, Wakatsuki T, Suenaga M, et al
    Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer.
    Int J Cancer. 2019 Apr 9. doi: 10.1002/ijc.32320.
    PubMed     Abstract available


  160. ZUR HAUSEN H, Bund T, de Villiers EM
    Specific nutritional infections early in life as risk factors for human colon and breast cancers several decades later.
    Int J Cancer. 2019;144:1574-1583.
    PubMed    


  161. FIEDLER D, Heselmeyer-Haddad K, Hirsch D, Hernandez LS, et al
    Single-cell genetic analysis of clonal dynamics in colorectal adenomas indicates CDX2 gain as a predictor of recurrence.
    Int J Cancer. 2019;144:1561-1573.
    PubMed     Abstract available


  162. PEREA J, Garcia JL, Corchete L, Lumbreras E, et al
    Redefining synchronous colorectal cancers based on tumor clonality.
    Int J Cancer. 2019;144:1596-1608.
    PubMed     Abstract available


    March 2019
  163. UNGARO F, Colombo P, Massimino L, Ugolini GS, et al
    Lymphatic endothelium contributes to colorectal cancer growth via the soluble matrisome component GDF11.
    Int J Cancer. 2019 Mar 19. doi: 10.1002/ijc.32286.
    PubMed     Abstract available


  164. SUGIYAMA H, Misumi M, Brenner A, Grant EJ, et al
    Radiation risk of incident colorectal cancer by anatomical site among atomic bomb survivors: 1958-2009.
    Int J Cancer. 2019 Mar 15. doi: 10.1002/ijc.32275.
    PubMed     Abstract available


  165. DIZDAR L, Werner TA, Drusenheimer JC, Mohlendick B, et al
    BRAF(V600E) mutation: A promising target in colorectal neuroendocrine carcinoma.
    Int J Cancer. 2019;144:1379-1390.
    PubMed     Abstract available


  166. BALAVARCA Y, Weigl K, Thomsen H, Brenner H, et al
    Performance of individual and joint risk stratification by an environmental risk score and a genetic risk score in a colorectal cancer screening setting.
    Int J Cancer. 2019 Mar 14. doi: 10.1002/ijc.32272.
    PubMed     Abstract available


  167. EL KINANY K, Huybrechts I, Kampman E, Boudouaya HA, et al
    Concordance with the World Cancer Research Fund/American Institute for Cancer Research recommendations for cancer prevention and colorectal cancer risk in Morocco: A large, population-based case-control study.
    Int J Cancer. 2019 Mar 12. doi: 10.1002/ijc.32263.
    PubMed     Abstract available


  168. XIN J, Du M, Gu D, Ge Y, et al
    Combinations of Single Nucleotide Polymorphisms Identified in Genome-wide Association Studies Determine Risk for Colorectal Cancer.
    Int J Cancer. 2019 Mar 12. doi: 10.1002/ijc.32267.
    PubMed     Abstract available


  169. TOKUNAGA R, Cao S, Naseem M, Battaglin F, et al
    AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: a meta-analysis using TRIBE, MAVERICC, and FIRE3.
    Int J Cancer. 2019 Mar 11. doi: 10.1002/ijc.32261.
    PubMed     Abstract available


  170. LI S, Shi X, Chen M, Xu N, et al
    Angiogenin promotes colorectal cancer metastasis via tiRNA production.
    Int J Cancer. 2019 Mar 3. doi: 10.1002/ijc.32245.
    PubMed     Abstract available


  171. NANDA N, Mahmood S, Bhatia A, Mahmood A, et al
    Chemopreventive role of olive oil in colon carcinogenesis by targeting noncoding RNAs and methylation machinery.
    Int J Cancer. 2019;144:1180-1194.
    PubMed     Abstract available


    February 2019
  172. SUN B, Zhou Y, Fang Y, Li Z, et al
    Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes.
    Int J Cancer. 2019 Feb 8. doi: 10.1002/ijc.32196.
    PubMed     Abstract available


  173. ALNABULSI A, Cash B, Hu Y, Silina L, et al
    The expression of brown fat associated proteins in colorectal cancer and the relationship of uncoupling protein 1 with prognosis.
    Int J Cancer. 2019 Feb 8. doi: 10.1002/ijc.32198.
    PubMed     Abstract available


  174. BARRY EL, Lund JL, Westreich D, Mott LA, et al
    Body mass index, calcium supplementation and risk of colorectal adenomas.
    Int J Cancer. 2019;144:448-458.
    PubMed     Abstract available


    January 2019
  175. ANTELO M, Golubicki M, Roca E, Mendez G, et al
    Lynch-like syndrome is as frequent as Lynch syndrome in early-onset non-familial non-polyposis colorectal cancer.
    Int J Cancer. 2019 Jan 29. doi: 10.1002/ijc.32160.
    PubMed     Abstract available


  176. GEIJSEN AJMR, Brezina S, Keski-Rahkonen P, Baierl A, et al
    Plasma metabolites associated with colorectal cancer: A discovery-replication strategy.
    Int J Cancer. 2019 Jan 21. doi: 10.1002/ijc.32146.
    PubMed     Abstract available


  177. CHENG X, Jin Z, Ji X, Shen X, et al
    ETS variant 5 promotes colorectal cancer angiogenesis by targeting platelet-derived growth factor BB.
    Int J Cancer. 2019 Jan 16. doi: 10.1002/ijc.32071.
    PubMed     Abstract available


  178. SOW HS, Benonisson H, Breukel C, Visser R, et al
    FcgammaR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model.
    Int J Cancer. 2019;144:345-354.
    PubMed     Abstract available


  179. HOFFMEISTER M, Holleczek B, Stock C, Zwink N, et al
    Utilization and determinants of follow-up colonoscopies within 6 years after screening colonoscopy: Prospective cohort study.
    Int J Cancer. 2019;144:402-410.
    PubMed     Abstract available


  180. DEVAUD C, Tilkin-Mariame AF, Vignolle-Vidoni A, Souleres P, et al
    FAK alternative splice mRNA variants expression pattern in colorectal cancer.
    Int J Cancer. 2019 Jan 10. doi: 10.1002/ijc.32120.
    PubMed     Abstract available


  181. WONG R, Tie J, Lee M, Cohen J, et al
    The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with non-specific findings on standard investigations.
    Int J Cancer. 2019 Jan 10. doi: 10.1002/ijc.32117.
    PubMed     Abstract available


  182. YAN C, Huang WY, Boudreau J, Mayavannan A, et al
    IL-17R deletion predicts high-grade colorectal cancer and poor clinical outcomes.
    Int J Cancer. 2019 Jan 10. doi: 10.1002/ijc.32122.
    PubMed     Abstract available


  183. SONG M, Ou FS, Zemla TJ, Hull MA, et al
    Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance).
    Int J Cancer. 2019 Jan 8. doi: 10.1002/ijc.32113.
    PubMed     Abstract available


  184. JORISSEN RN, Croxford M, Jones IT, Ward RL, et al
    Evaluation of the Transferability of Survival Calculators for Stage II/III Colon Cancer Across Healthcare Systems.
    Int J Cancer. 2019 Jan 8. doi: 10.1002/ijc.32100.
    PubMed     Abstract available


  185. BRANDAO RD, Mensaert K, Lopez-Perolio I, Tserpelis D, et al
    Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes.
    Int J Cancer. 2019 Jan 8. doi: 10.1002/ijc.32114.
    PubMed     Abstract available


  186. MODEST DP, Rivera F, Bachet JB, de Braud F, et al
    Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: a retrospective analysis of two randomised trials.
    Int J Cancer. 2019 Jan 7. doi: 10.1002/ijc.32110.
    PubMed     Abstract available


  187. MYTE R, Gylling B, Haggstrom J, Haggstrom C, et al
    Metabolic factors and the risk of colorectal cancer by KRAS and BRAF mutation status.
    Int J Cancer. 2019 Jan 7. doi: 10.1002/ijc.32104.
    PubMed     Abstract available


  188. HU J, Shan Y, Ma J, Pan Y, et al
    LncRNA ST3Gal6-AS1/ST3Gal6 axis mediates colorectal cancer progression by regulating alpha-2, 3 sialylation via PI3K/Akt signaling.
    Int J Cancer. 2019 Jan 7. doi: 10.1002/ijc.32103.
    PubMed     Abstract available


    December 2018
  189. WARD HA, Murphy N, Weiderpass E, Leitzmann MF, et al
    Gallstones and incident colorectal cancer in a large pan-European cohort study.
    Int J Cancer. 2018 Dec 26. doi: 10.1002/ijc.32090.
    PubMed     Abstract available


  190. VICENTINI M, Zorzi M, Bovo E, Mancuso P, et al
    Impact of screening programme using the faecal immunochemical test on stage of colorectal cancer. Results from the IMPATTO study.
    Int J Cancer. 2018 Dec 26. doi: 10.1002/ijc.32089.
    PubMed     Abstract available


  191. REN A, Sun S, Li S, Chen T, et al
    Genetic variants in SLC22A3 contribute to the susceptibility to colorectal cancer.
    Int J Cancer. 2018 Dec 18. doi: 10.1002/ijc.32079.
    PubMed     Abstract available


  192. ZAIMENKO I, Jaeger C, Brenner H, Chang-Claude J, et al
    Non-invasive metastasis prognosis from plasma metabolites in stage II colorectal cancer patients: the DACHS study.
    Int J Cancer. 2018 Dec 18. doi: 10.1002/ijc.32076.
    PubMed     Abstract available


  193. GAO X, Wilsgaard T, Jansen EH, Holleczek B, et al
    Pre-diagnostic derivatives of reactive oxygen metabolites and the occurrence of lung, colorectal, breast and prostate cancer: An individual participant data meta-analysis of two large population-based studies.
    Int J Cancer. 2018 Dec 18. doi: 10.1002/ijc.32073.
    PubMed     Abstract available


  194. HAMERS FF, Assogba FAG, Rogel A
    Implementation and organization of cancer screening in France.
    Int J Cancer. 2018;143:3281.
    PubMed    


  195. YANG T, Li X, Montazeri Z, Little J, et al
    Gene-environment interactions and colorectal cancer risk: an umbrella review of systematic reviews and meta-analyses of observational studies.
    Int J Cancer. 2018 Dec 11. doi: 10.1002/ijc.32057.
    PubMed     Abstract available


  196. ARAGHI M, Soerjomataram I, Jenkins M, Brierley J, et al
    Global trends in colorectal cancer mortality: projections to the year 2035.
    Int J Cancer. 2018 Dec 10. doi: 10.1002/ijc.32055.
    PubMed     Abstract available


  197. ROSEWEIR AK, Clark J, McSorley ST, van Wyk HC, et al
    The association between markers of tumor cell metabolism, the tumor microenvironment and outcomes in patients with colorectal cancer.
    Int J Cancer. 2018 Dec 6. doi: 10.1002/ijc.32045.
    PubMed     Abstract available


  198. PETIMAR J, Tabung FK, Valeri L, Rosner B, et al
    Mediation of Associations Between Adiposity and Colorectal Cancer Risk by Inflammatory and Metabolic Biomarkers.
    Int J Cancer. 2018 Dec 6. doi: 10.1002/ijc.32047.
    PubMed     Abstract available


  199. JIANG W, Cai M, Li S, Bei J, et al
    Universal screening for Lynch Syndrome in a large consecutive cohort of Chinese colorectal cancer patients: high prevalence and unique molecular features.
    Int J Cancer. 2018 Dec 6. doi: 10.1002/ijc.32044.
    PubMed     Abstract available


  200. IBRAHIM A, Hugerth L, Hases L, Saxena A, et al
    Colitis-induced colorectal cancer and intestinal epithelial estrogen receptor beta impact gut microbiota diversity.
    Int J Cancer. 2018 Dec 4. doi: 10.1002/ijc.32037.
    PubMed     Abstract available


  201. GRAF ME, Sookthai D, Johnson T, Schubel R, et al
    Pre-diagnostic plasma concentrations of Fibrinogen, sGPIIb/IIIa, sP-selectin, sThrombomodulin, Thrombopoietin in relation to cancer risk: Findings from a large prospective study.
    Int J Cancer. 2018;143:2659-2667.
    PubMed     Abstract available


  202. KAYSER K, Degenhardt F, Holzapfel S, Horpaopan S, et al
    Copy number variation analysis and targeted NGS in 77 families with suspected Lynch syndrome reveals novel potential causative genes.
    Int J Cancer. 2018;143:2800-2813.
    PubMed     Abstract available


    November 2018
  203. DAI Z, Zhang J, Wu Q, Chen J, et al
    The role of microbiota in the development of colorectal cancer.
    Int J Cancer. 2018 Nov 26. doi: 10.1002/ijc.32017.
    PubMed     Abstract available


  204. EIDE PW, Eilertsen IA, Sveen A, Lothe RA, et al
    Long non-coding RNA MIR31HG is a bona fide prognostic marker with colorectal cancer cell-intrinsic properties.
    Int J Cancer. 2018 Nov 17. doi: 10.1002/ijc.31998.
    PubMed     Abstract available


  205. ZHU L, Yan F, Wang Z, Dong H, et al
    Genome-wide DNA methylation profiling of primary colorectal laterally spreading tumors identifies disease-specific epimutations on common pathways.
    Int J Cancer. 2018;143:2488-2498.
    PubMed     Abstract available


  206. WANG G, Wang Q, Huang Q, Chen Y, et al
    Upregulation of mtSSB by interleukin-6 promotes cell growth through mitochondrial biogenesis-mediated telomerase activation in colorectal cancer.
    Int J Cancer. 2018 Nov 10. doi: 10.1002/ijc.31978.
    PubMed     Abstract available


  207. FU X, Huang Y, Fan X, Deng Y, et al
    Demographic Trends and KRAS/BRAF(V600E) Mutations in Colorectal Cancer Patients of South China: a Single-site Report.
    Int J Cancer. 2018 Nov 10. doi: 10.1002/ijc.31973.
    PubMed     Abstract available


  208. AMITAY EL, Cuk K, Niedermaier T, Weigl K, et al
    Factors Associated with False Positive Fecal Immunochemical Tests in a Large German Colorectal Cancer Screening Study.
    Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31972.
    PubMed     Abstract available


  209. SUENAGA M, Cao S, Zhang W, Yang D, et al
    Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients.
    Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31968.
    PubMed     Abstract available


  210. ETEMADI A, Abnet CC, Graubard BI, Beane-Freeman L, et al
    Anatomical subsite can modify the association between meat and meat compounds and risk of colorectal adenocarcinoma: Findings from three large US cohorts.
    Int J Cancer. 2018;143:2261-2270.
    PubMed     Abstract available


    October 2018
  211. FUJI T, Umeda Y, Nyuya A, Taniguchi F, et al
    Detection of Circulating MicroRNAs with Ago2 Complexes to Monitor the Tumor Dynamics of Colorectal Cancer Patients during Chemotherapy.
    Int J Cancer. 2018 Oct 31. doi: 10.1002/ijc.31960.
    PubMed     Abstract available


  212. YANG Y, Cai Q, Shu XO, Steinwandel MD, et al
    Prospective Study of Oral Microbiome and Colorectal Cancer Risk in Low-income and African American Populations.
    Int J Cancer. 2018 Oct 26. doi: 10.1002/ijc.31941.
    PubMed     Abstract available


  213. ABDUL-WAHID A, Cydzik M, Fischer NW, Prodeus A, et al
    Serum-derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re-modeling of the extracellular matrix that favors the engraftment of CEA-expressing tumor cells.
    Int J Cancer. 2018;143:1963-1977.
    PubMed     Abstract available


  214. VACCARO CA, Lopez-Kostner F, Valle AD, Palmero EI, et al
    From colorectal cancer pattern to the characterization of individuals at risk: picture for genetic research in Latin America.
    Int J Cancer. 2018 Oct 10. doi: 10.1002/ijc.31920.
    PubMed     Abstract available


  215. RATJEN I, Shivappa N, Schafmayer C, Burmeister G, et al
    Association between the dietary inflammatory index and all-cause mortality in colorectal cancer long-term survivors.
    Int J Cancer. 2018 Oct 10. doi: 10.1002/ijc.31919.
    PubMed     Abstract available


    September 2018
  216. BORMANN F, Stinzing S, Tierling S, Morkel M, et al
    Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancer.
    Int J Cancer. 2018 Sep 25. doi: 10.1002/ijc.31892.
    PubMed     Abstract available


  217. GARGALLO CJ, Lanas A, Carrera-Lasfuentes P, Ferrandez A, et al
    Genetic susceptibility in the development of colorectal adenomas according to family history of colorectal cancer.
    Int J Cancer. 2018 Sep 8. doi: 10.1002/ijc.31858.
    PubMed     Abstract available


  218. KLEIN CH, Truxius DC, Vogel HA, Harizanova J, et al
    PDEdelta inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas.
    Int J Cancer. 2018 Sep 8. doi: 10.1002/ijc.31859.
    PubMed     Abstract available


    August 2018
  219. PRASETYANTI PR, van Hooff SR, van Herwaarden T, de Vries N, et al
    Capturing Colorectal Cancer Inter-Tumor Heterogeneity in Patient-Derived Xenograft (PDX) Models.
    Int J Cancer. 2018 Aug 27. doi: 10.1002/ijc.31767.
    PubMed     Abstract available


  220. SONG M, Sasazuki S, Camargo MC, Shimazu T, et al
    Circulating Inflammatory Markers and Colorectal Cancer Risk: A Prospective Case-cohort Study in Japan.
    Int J Cancer. 2018 Aug 21. doi: 10.1002/ijc.31821.
    PubMed     Abstract available


  221. EILERTSEN IA, Sveen A, Stromme JM, Skotheim RI, et al
    Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer.
    Int J Cancer. 2018 Aug 19. doi: 10.1002/ijc.31809.
    PubMed     Abstract available


  222. KIVES Z, Juhasz K, Csakvari T, Agoston I, et al
    Cancer screening policy in Hungary.
    Int J Cancer. 2018;143:1003-1004.
    PubMed    


  223. RADA-FERNANDEZ DE JAUREGUI D, Evans CEL, Jones P, Greenwood DC, et al
    Common dietary patterns and risk of cancers of the colon and rectum: Analysis from the United Kingdom Women's Cohort Study (UKWCS).
    Int J Cancer. 2018;143:773-781.
    PubMed     Abstract available


  224. BROUWER NPM, Bos ACRK, Lemmens VEPP, Tanis PJ, et al
    An overview of 25 years of incidence, treatment and outcome of colorectal cancer patients.
    Int J Cancer. 2018 Aug 10. doi: 10.1002/ijc.31785.
    PubMed     Abstract available


  225. CAI M, Zhang H, Hou L, Gao W, et al
    Inhibiting homologous recombination decreases extrachromosomal amplification but has no effect on intrachromosomal amplification in methotrexate-resistant colon cancer cells.
    Int J Cancer. 2018 Aug 2. doi: 10.1002/ijc.31781.
    PubMed     Abstract available


  226. KWOK ZH, Roche V, Chew XH, Fadieieva A, et al
    A non-canonical tumor suppressive role for the long non-coding RNA MALAT1 in colon and breast cancers.
    Int J Cancer. 2018;143:668-678.
    PubMed     Abstract available


    July 2018
  227. ROSEWEIR AK, Kong CY, Park JH, Bennett L, et al
    A novel tumor-based epithelial-to-mesenchymal transition score that associates with prognosis and metastasis in patients with stage II/III colorectal cancer.
    Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31739.
    PubMed     Abstract available


  228. YUAN Y, Qi G, Shen H, Guo A, et al
    Clinical significance and biological function of WD repeat domain 54 as an oncogene in colorectal cancer.
    Int J Cancer. 2018 Jul 10. doi: 10.1002/ijc.31736.
    PubMed     Abstract available


  229. CHEN C, Stock C, Hoffmeister M, Brenner H, et al
    How long does it take until the effects of endoscopic screening on colorectal cancer mortality are fully disclosed? : A Markov model study.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31716.
    PubMed     Abstract available


  230. PARK YL, Kim HP, Cho YW, Min DW, et al
    Activation of WNT/beta-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31662.
    PubMed     Abstract available


  231. PAPANTONIOU K, Devore EE, Massa J, Strohmaier S, et al
    Rotating Night Shift work and Colorectal Cancer Risk in the Nurses' Health Studies.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31655.
    PubMed     Abstract available


  232. AHADOVA A, Gallon R, Gebert J, Ballhausen A, et al
    Three molecular pathways model colorectal carcinogenesis in Lynch syndrome.
    Int J Cancer. 2018;143:139-150.
    PubMed     Abstract available


    June 2018
  233. BOYSEN AK, Spindler KL, Hoyer M, Mortensen FV, et al
    Metastasis directed therapy for liver and lung metastases from colorectal cancer - a population based study.
    Int J Cancer. 2018 Jun 19. doi: 10.1002/ijc.31626.
    PubMed     Abstract available


  234. DASHTI SG, Win AK, Hardikar SS, Glombicki SE, et al
    Physical activity and the risk of colorectal cancer in Lynch syndrome.
    Int J Cancer. 2018 Jun 14. doi: 10.1002/ijc.31611.
    PubMed     Abstract available


  235. MAO Y, Feng Q, Zheng P, Yang L, et al
    Low Tumor Infiltrating Mast Cell Density Confers Prognostic Benefit and Reflects Immunoactivation in Colorectal Cancer.
    Int J Cancer. 2018 Jun 6. doi: 10.1002/ijc.31613.
    PubMed     Abstract available


  236. FORMICA V, Zaniboni A, Loupakis F, Roselli M, et al
    Non-inferiority of three months vs six months of oxaliplatin-based adjuvant chemotherapy for resected colon cancer. How should IDEA findings affect clinical practice?
    Int J Cancer. 2018 Jun 6. doi: 10.1002/ijc.31616.
    PubMed     Abstract available


    May 2018
  237. GYLLING B, Myte R, Ulvik A, Ueland PM, et al
    One-carbon metabolite ratios as functional B-vitamin markers and in relation to colorectal cancer risk.
    Int J Cancer. 2018 May 22. doi: 10.1002/ijc.31606.
    PubMed     Abstract available


  238. HUANG X, Yang Y, Zhao Y, Cao D, et al
    RhoA-stimulated intra-capillary morphology switch facilitates the arrest of individual circulating tumor cells.
    Int J Cancer. 2018;142:2094-2105.
    PubMed     Abstract available


  239. TAYLOR ES, McCall JL, Shen S, Girardin A, et al
    Prognostic roles for IL-2-producing and CD69(+) T cell subsets in colorectal cancer patients.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31598.
    PubMed     Abstract available


    April 2018
  240. MURPHY N, Achaintre D, Zamora-Ros R, Jenab M, et al
    A Prospective Evaluation of Plasma Polyphenol Levels and Colon Cancer Risk.
    Int J Cancer. 2018 Apr 26. doi: 10.1002/ijc.31563.
    PubMed     Abstract available


  241. CHEN L, Pan X, Hu X, Zhang YH, et al
    Gene expression differences among different MSI statuses in colorectal cancer.
    Int J Cancer. 2018 Apr 26. doi: 10.1002/ijc.31554.
    PubMed     Abstract available


  242. BARRUBES L, Babio N, Mena-Sanchez G, Toledo E, et al
    Dairy product consumption and risk of colorectal cancer in an older Mediterranean population at high cardiovascular risk.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31540.
    PubMed     Abstract available


  243. TRIFF K, McLean MW, Callaway E, Goldsby J, et al
    Dietary fat and fiber interact to uniquely modify global histone post-translational epigenetic programming in a rat colon cancer progression model.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31525.
    PubMed     Abstract available


  244. WU JC, Tsai ML, Lai CS, Lo CY, et al
    Polymethoxyflavones prevent benzo[a]pyrene/dextran sodium sulfate-induced colorectal carcinogenesis through modulating xenobiotic metabolism and ameliorate autophagic defect in ICR mice.
    Int J Cancer. 2018;142:1689-1701.
    PubMed     Abstract available


  245. LIU X, Zhou W, Zhang X, Ding Y, et al
    1-L-MT, an IDO inhibitor, prevented colitis-associated cancer by inducing CDC20 inhibition-mediated mitotic death of colon cancer cells.
    Int J Cancer. 2018 Apr 1. doi: 10.1002/ijc.31417.
    PubMed     Abstract available


  246. TABATABAEI M, Mosaffa N, Ghods R, Nikoo S, et al
    Vaccination with human amniotic epithelial cells confer effective protection in a murine model of Colon adenocarcinoma.
    Int J Cancer. 2018;142:1453-1466.
    PubMed     Abstract available


    March 2018
  247. LI X, Guo X, Li D, Du X, et al
    Multi-regional Sequencing Reveals Intratumor Heterogeneity and Positive Selection of Somatic mtDNA Mutations in Hepatocellular Carcinoma and Colorectal Cancer.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31395.
    PubMed     Abstract available


  248. FADDA A, Gentilini D, Moi L, Barault L, et al
    Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor.
    Int J Cancer. 2018 Mar 15. doi: 10.1002/ijc.31380.
    PubMed     Abstract available


  249. ZHOU M, Liu X, Li Z, Huang Q, et al
    Caspase-3 regulates the migration, invasion, and metastasis of colon cancer cells.
    Int J Cancer. 2018 Mar 10. doi: 10.1002/ijc.31374.
    PubMed     Abstract available


  250. PAN P, Oshima K, Huang YW, Agle KA, et al
    Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors.
    Int J Cancer. 2018 Mar 9. doi: 10.1002/ijc.31366.
    PubMed     Abstract available


    February 2018
  251. MARQUEZ J, Fernandez-Pineiro I, Arauzo-Bravo MJ, Poschmann G, et al
    Targeting liver sinusoidal endothelial cells with miR-20a-loaded nanoparticles reduces murine colon cancer metastasis to the liver.
    Int J Cancer. 2018 Feb 28. doi: 10.1002/ijc.31343.
    PubMed     Abstract available


  252. KABAT GC, Kim MY, Stefanick M, Ho GYF, et al
    Metabolic obesity phenotypes and risk of colorectal cancer in postmenopausal women.
    Int J Cancer. 2018 Feb 27. doi: 10.1002/ijc.31345.
    PubMed     Abstract available


  253. SHU X, Xiang YB, Rothman N, Yu D, et al
    Prospective study of blood metabolites associated with colorectal cancer risk.
    Int J Cancer. 2018 Feb 26. doi: 10.1002/ijc.31341.
    PubMed     Abstract available


  254. WU S, Meng Q, Zhang C, Sun H, et al
    DR4 mediates the progression, invasion, metastasis and survival of colorectal cancer through the Sp1/NF1 switch axis on genomic locus.
    Int J Cancer. 2018 Feb 15. doi: 10.1002/ijc.31318.
    PubMed     Abstract available


  255. KASHINO I, Akter S, Mizoue T, Sawada N, et al
    Coffee drinking and colorectal cancer and its subsites: A pooled analysis of 8 cohort studies in Japan.
    Int J Cancer. 2018 Feb 15. doi: 10.1002/ijc.31320.
    PubMed     Abstract available


  256. KOREHISA S, Oki E, Iimori M, Nakaji Y, et al
    Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
    Int J Cancer. 2018;142:822-832.
    PubMed     Abstract available


  257. LEW JB, James D, St John B, Macrae FA, et al
    Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
    Int J Cancer. 2018 Feb 14. doi: 10.1002/ijc.31314.
    PubMed     Abstract available


  258. AMSHOFF Y, Maskarinec G, Shvetsov YB, Raquinio PH, et al
    Type 2 Diabetes and Colorectal Cancer Survival: The Multiethnic Cohort.
    Int J Cancer. 2018 Feb 14. doi: 10.1002/ijc.31311.
    PubMed     Abstract available


  259. SCHULLEHNER J, Hansen B, Thygesen M, Pedersen CB, et al
    Nitrate in drinking water and colorectal cancer risk: A nationwide population-based cohort study.
    Int J Cancer. 2018 Feb 13. doi: 10.1002/ijc.31306.
    PubMed     Abstract available


  260. FRANSGAARD T, Thygesen LC, Gogenur I
    Association between metformin use after surgery for colorectal cancer and oncological outcomes: A nationwide register-based study.
    Int J Cancer. 2018 Feb 13. doi: 10.1002/ijc.31305.
    PubMed     Abstract available


    January 2018
  261. O'BRIEN SJ, Carter JV, Burton JF, Oxford BG, et al
    The role of the miR-200 Family in Epithelial-Mesenchymal Transition in Colorectal Cancer: A Systematic Review.
    Int J Cancer. 2018 Jan 31. doi: 10.1002/ijc.31282.
    PubMed     Abstract available


  262. ISHIKAWA T, Okayama T, Sakamoto N, Ideno M, et al
    Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer.
    Int J Cancer. 2018 Jan 31. doi: 10.1002/ijc.31285.
    PubMed     Abstract available


  263. BUTT J, Jenab M, Willhauck-Fleckenstein M, Michel A, et al
    Prospective evaluation of antibody response to Streptococcus gallolyticus and risk of colorectal cancer.
    Int J Cancer. 2018 Jan 29. doi: 10.1002/ijc.31283.
    PubMed     Abstract available


  264. MA H, Wu Z, Peng J, Li Y, et al
    Inhibition of SLC1A5 sensitizes colorectal cancer to cetuximab.
    Int J Cancer. 2018 Jan 24. doi: 10.1002/ijc.31274.
    PubMed     Abstract available


  265. SETTE G, Salvati V, Giordani I, Pillozzi E, et al
    Conditionally reprogrammed cells (CRC) methodology does not allow the in vitro expansion of patient-derived primary and metastatic lung cancer cells.
    Int J Cancer. 2018 Jan 17. doi: 10.1002/ijc.31260.
    PubMed     Abstract available


  266. VAN SEBILLE YZA, Gibson RJ, Wardill HR, Ball IA, et al
    Dacomitinib-induced diarrhea: Targeting chloride secretion with crofelemer.
    Int J Cancer. 2018;142:369-380.
    PubMed     Abstract available


  267. BASU P, Ponti A, Anttila A, Ronco G, et al
    Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report.
    Int J Cancer. 2018;142:44-56.
    PubMed     Abstract available


    December 2017
  268. GIES A, Bhardwaj M, Stock C, Schrotz-King P, et al
    Quantitative Fecal Immunochemical Tests for Colorectal Cancer Screening.
    Int J Cancer. 2017 Dec 26. doi: 10.1002/ijc.31233.
    PubMed     Abstract available


  269. LIU W, Wang S, Sun Q, Yang Z, et al
    DCLK1 Promotes Epithelial-Mesenchymal Transition via the PI3K/Akt/NF-kappaB Pathway in Colorectal Cancer.
    Int J Cancer. 2017 Dec 26. doi: 10.1002/ijc.31232.
    PubMed     Abstract available


  270. JI J, Sundquist J, Sundquist K
    Use of hormone replacement therapy improves the prognosis in patients with colorectal cancer: A population-based study in Sweden.
    Int J Cancer. 2017 Dec 22. doi: 10.1002/ijc.31228.
    PubMed     Abstract available


  271. FENG HC, Lin JY, Hsu SH, Lan WY, et al
    Low folate metabolic stress reprograms DNA methylation-activated sonic hedgehog signaling to mediate cancer stem cell-like signatures and invasive tumour stage-specific malignancy of human colorectal cancers.
    Int J Cancer. 2017;141:2537-2550.
    PubMed     Abstract available


  272. ZHOU R, Shao Z, Liu J, Zhan W, et al
    COPS5 and LASP1 Synergistically Interact to Down-regulate 14-3-3sigma Expression and Promote Colorectal Cancer Progression via Activating PI3K/AKT Pathway.
    Int J Cancer. 2017 Dec 11. doi: 10.1002/ijc.31206.
    PubMed     Abstract available


  273. SCHWINGSHACKL L, Schwedhelm C, Hoffmann G, Knuppel S, et al
    Food groups and risk of colorectal cancer.
    Int J Cancer. 2017 Dec 6. doi: 10.1002/ijc.31198.
    PubMed     Abstract available


  274. RAY AL, Berggren KL, Restrepo Cruz S, Gan GN, et al
    Inhibition of MK2 suppresses IL-1beta, IL-6, and TNF-alpha dependent colorectal cancer growth.
    Int J Cancer. 2017 Dec 2. doi: 10.1002/ijc.31191.
    PubMed     Abstract available


    November 2017
  275. BABAEI M, Balavarca Y, Jansen L, Lemmens V, et al
    Administration of Adjuvant Chemotherapy for Stage II-III Colon Cancer Patients: A European Population-based Study.
    Int J Cancer. 2017 Nov 21. doi: 10.1002/ijc.31168.
    PubMed     Abstract available


  276. YAMAUCHI M, Urabe Y, Ono A, Miki D, et al
    Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients.
    Int J Cancer. 2017 Nov 14. doi: 10.1002/ijc.31154.
    PubMed     Abstract available


  277. DI J, Yang H, Jiang B, Wang Z, et al
    Whole exome sequencing reveals intertumor heterogeneity and distinct genetic origins of sporadic synchronous colorectal cancer.
    Int J Cancer. 2017 Nov 6. doi: 10.1002/ijc.31140.
    PubMed     Abstract available


    October 2017
  278. ZHANG QL, Zhao LG, Li HL, Gao J, et al
    The joint effects of major lifestyle factors on colorectal cancer risk among Chinese men: A prospective cohort study.
    Int J Cancer. 2017 Oct 21. doi: 10.1002/ijc.31126.
    PubMed     Abstract available


  279. HOLCH JW, Ricard I, Stintzing S, Fischer von Weikersthal L, et al
    Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.
    Int J Cancer. 2017 Oct 19. doi: 10.1002/ijc.31114.
    PubMed     Abstract available


  280. NIELL N, Larriba MJ, Ferrer-Mayorga G, Sanchez-Perez I, et al
    The human PKP2/Plakophilin-2 gene is induced by Wnt/beta-catenin in normal and colon cancer-associated fibroblasts.
    Int J Cancer. 2017 Oct 16. doi: 10.1002/ijc.31104.
    PubMed     Abstract available


  281. HIDAYAT K, Yang CM, Shi BM
    Body Fatness at an Early Age and Risk of Colorectal Cancer.
    Int J Cancer. 2017 Oct 12. doi: 10.1002/ijc.31100.
    PubMed     Abstract available


  282. PAN R, Zhu M, Yu C, Lv J, et al
    Cancer incidence and mortality: A cohort study in China, 2008-2013.
    Int J Cancer. 2017;141:1315-1323.
    PubMed     Abstract available


  283. VARGAS-PARRA GM, Gonzalez-Acosta M, Thompson BA, Gomez C, et al
    Elucidating the molecular basis of MSH2-deficient tumors by combined germline and somatic analysis.
    Int J Cancer. 2017;141:1365-1380.
    PubMed     Abstract available


    September 2017
  284. TANSKANEN T, van den Berg L, Valimaki N, Aavikko M, et al
    Genome-wide association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci.
    Int J Cancer. 2017 Sep 28. doi: 10.1002/ijc.31076.
    PubMed     Abstract available


  285. POTHOULAKIS C, Torre-Rojas M, Duran-Padilla MA, Gevorkian J, et al
    CRHR2/Ucn2 signaling is a novel regulator of miR-7/YY1/Fas circuitry contributing to reversal of colorectal cancer cell resistance to Fas-mediated apoptosis.
    Int J Cancer. 2017 Sep 20. doi: 10.1002/ijc.31064.
    PubMed     Abstract available


  286. WANG W, Xiao X, Chen X, Huo Y, et al
    Tumor-suppressive miR-145 co-repressed by TCF4-beta-catenin and PRC2 complexes forms double-negative regulation loops with its negative regulators in colorectal cancer.
    Int J Cancer. 2017 Sep 16. doi: 10.1002/ijc.31056.
    PubMed     Abstract available


  287. JAYASEKARA H, English DR, Haydon A, Hodge AM, et al
    Associations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype.
    Int J Cancer. 2017 Sep 16. doi: 10.1002/ijc.31049.
    PubMed     Abstract available


  288. MA B, Gao P, Wang H, Xu Q, et al
    What has preoperative radio(chemo)therapy brought to localized rectal cancer patients in terms of perioperative and long-term outcomes over the past decades? A systematic review and meta-analysis based on 41,121 patients.
    Int J Cancer. 2017;141:1052-1065.
    PubMed     Abstract available


  289. VEDELD HM, Merok M, Jeanmougin M, Danielsen SA, et al
    CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers.
    Int J Cancer. 2017;141:967-976.
    PubMed     Abstract available


    July 2017
  290. SCHIRRIPA M, Zhang W, Heinemann V, Cao S, et al
    Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.
    Int J Cancer. 2017;141:383-392.
    PubMed     Abstract available


  291. GU F, Zhang H, Hyland PL, Berndt S, et al
    Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.
    Int J Cancer. 2017 Jul 12. doi: 10.1002/ijc.30883.
    PubMed     Abstract available


  292. CABEL L, Bidard FC, Servois V, Cacheux W, et al
    HPV circulating tumor DNA to monitor the efficacy of anti-PD-1 therapy in metastatic squamous cell carcinoma of the anal canal: A case report.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30863.
    PubMed     Abstract available


    June 2017
  293. VAN SEBILLE YZA, Gibson RJ, Wardill HR, Secombe KR, et al
    Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats.
    Int J Cancer. 2017;140:2820-2829.
    PubMed     Abstract available


    April 2017
  294. DE MARTEL C, Plummer M, Vignat J, Franceschi S, et al
    Worldwide burden of cancer attributable to HPV by site, country and HPV type.
    Int J Cancer. 2017 Apr 1. doi: 10.1002/ijc.30716.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: